GENEQ GLOBAL LTD

What GENEQ GLOBAL LTD does

GENEQ Global Ltd is a London-headquartered health equity consultancy founded in 2025 by Simeón Scott Baker (CEO), Dr Heinner Guio (CMO), and Dr Manuel Corpas (CSO). The firm advises governments, health systems, and life sciences companies on the design, pilot, and scale-up of genomic screening and precision medicine programs, with particular specialization in newborn genomic sequencing and equity-centered implementation. Its service catalogue spans international genomics implementation consultancy, newborn sequencing program advisory, and precision medicine/pharmacogenomics strategic planning, delivered through multi-phase engagements (situational analysis, pilot design, implementation and evaluation, scale-up planning). The company's value proposition rests on a co-production model with national stakeholders — technical committees, ethics boards, and finance ministries — rather than standardized blueprint deployment.

The core technology layer combines advanced genome sequencing solutions and bioinformatics-based interpretation of complex genomic datasets, augmented by two proprietary methodologies: the HEIM (Health Equity Informative Metrics) Framework, which measures research equity across discovery, clinical trials, and knowledge connectivity, and GEDA (Genomic Equity Data Assessment), which audits representation gaps in genomic datasets against global disease burden distributions. The firm also sells direct-to-consumer exome and genome testing through home and pharmacy channels covering ancestry, medical conditions, and precision medicine screening. The team draws on learnings from 10 active newborn sequencing programs, including the UK's Generation Study, and analysis of 520 publications on newborn genomic sequencing implementation.

Revenue is generated primarily through bespoke professional services engagements with enterprise and government clients, complemented by the consumer-facing DTC testing line. Distribution is entirely direct enterprise sales with no intermediary channel partners; pricing is not publicly disclosed and quotes are provided per engagement. Marketing is content-driven, centered on thought leadership via blog, LinkedIn, email newsletter, and industry event participation (Madrid, San Francisco, London, Boston). Operating geographies span the UK, continental Europe (Spain), and North America (USA), with no funding rounds, M&A, or institutional investors disclosed.

Name

GENEQ GLOBAL LTD

Legal name

GENEQ Global Ltd

Website

https://geneqglobal.com

Company type

Private

Founded year

2025

Operating status

Operating

Short description

GENEQ Global Ltd is a London-based genomics and precision medicine consultancy, founded in 2025, providing end-to-end program design, equity assessment, and newborn sequencing advisory services to governments, health systems, and life sciences companies globally.

Ownership category

akta.pro rank

Product category

Genomics Consulting Services

NAICS

Other Scientific and Technical Consulting Services (54169), Medical Laboratories (621511)

SIC

Services-Management Services (8741), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Population Genomics & Preventive Precision Health Programs (HLAAANAL)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Genomics consulting
• Precision medicine
• Health equity genomics
• Genome sequencing services
• Bioinformatics analytics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Genomics Implementation Consultancy: End-to-end consultancy services helping countries and companies design and implement genomic screening programs. Revenue generated through project-based consulting engagements with governments, health systems, and institutional clients.
2. Newborn Sequencing Program Consultancy: Specialized consultancy supporting Ministries of Health and National Program Leaders to design, pilot and scale equitable newborn genomic screening programs. Revenue from multi-phase implementation support engagements.
3. Precision Medicine & Pharmacogenomics Services: Strategic planning and implementation support for countries and companies building precision medicine capabilities, providing research, data and equity-led proposals.
4. Direct-to-Consumer Genomic Testing: Direct to consumer exome and genome testing for ancestry, medical conditions, and precision medicine screening, sold to individuals via home testing or pharmacy channels.
5. Genomic Equity Data Assessment (GEDA): Systematic evaluation services for genomic datasets, screening programmes and research initiatives. Typical engagements include national screening programme equity reviews, biobank diversity assessments, clinical genomics service audits, and research portfolio gap analysis.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

GENEQ Global is a health equity genomics consultancy that helps governments, health systems, and life sciences organisations design and implement precision medicine and genomics programmes. Its offerings span precision genome sequencing, clinical genomic data interpretation, direct-to-consumer exome and genome testing, and advisory engagements such as newborn sequencing programme consultancy and international genomics implementation. The firm also develops proprietary analytical frameworks, including the Health Equity Informative Metrics (HEIM) framework and the Genomic Equity Data Assessment (GEDA), to embed equity considerations into genomic data and programme design.

Product overview

GENEQ Global offers a portfolio of genome sequencing products and consultancy services focused on health equity. The core products include Precision Genome Sequencing and Clinical Genomic Data Insights for data analysis, the Health Equity Informative Metrics (HEIM) Framework for measuring research equity across the biomedical pipeline, Genomic Equity Data Assessment (GEDA) for evaluating representation gaps in genomic datasets, and Direct to Consumer Exome and Genome Testing. These are complemented by three consultancy services: International Genomics Implementation and Consultancy, Newborn Sequencing Program Consultancy, and Precision Medicine and Pharmacogenomics services.

Differentiator

Problem solved

Functional benefit

Brands

• HEIM (Health Equity Informative Metrics): A framework that measures research equity across the full biomedical pipeline, from discovery and clinical trials to scientific knowledge, revealing where research aligns with real global health needs.
• GEDA (Genomic Equity Data Assessment)

Products and services

• Precision Genome Sequencing
• Clinical Genomic Data Insights
• Health Equity Informative Metrics (HEIM) Framework
• Genomic Equity Data Assessment (GEDA)
• Direct-to-Consumer Exome and Genome Testing
• International Genomics Implementation and Consultancy
• Newborn Sequencing Programme Consultancy
• Precision Medicine and Pharmacogenomics

Quantifiable outcome

• 10 active newborn sequencing programs supported, including UK's Generation Study
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• McKinsey & Company - Healthcare Practice:
• Genetic Alliance: US-based nonprofit advocacy organization focused on genetic health equity, access, and patient engagement in genomics policy. Adjacent peer to GENEQ's equity-focused positioning in genomics, sharing mission alignment around equitable access to genomic medicine.

Direct peers

• Genomics England: UK government-owned company running the Generation Study and the NHS Genomic Medicine Service. Most direct peer to GENEQ's newborn sequencing consultancy work; both target Ministries of Health with end-to-end genomic program implementation, though Genomics England operates at much larger scale as a public body.
• Color Health: US-based population genomics and clinical genetic testing company offering population-scale screening programs to employers, health systems, and public health initiatives. Comparable to GENEQ in combining genomic testing with population-health program delivery and equity-centered positioning.
• GeneDx: Genomics-focused clinical laboratory specializing in rare disease and pediatric genomic sequencing, with growing newborn screening offerings. Comparable to GENEQ in delivering genomic insights at the clinical-population interface and serving health-system and public-health buyers.
• Concert Genetics: US-based company providing data, evidence, and policy expertise to support genetic testing coverage, access, and equity. Comparable to GENEQ in combining genomic data expertise with policy/access advisory for payers, providers, and public programs.

Broad incumbents

• Illumina: Dominant DNA sequencing technology platform provider with growing footprint in population genomics programs through partnerships with national initiatives. Comparable as ecosystem participant enabling the same national screening programs GENEQ consults on, though operating at the platform/instrument layer.
• 23andMe: Leading direct-to-consumer genetic testing company offering ancestry, health, and trait reports. Comparable to GENEQ's DTC exome/genome testing stream but at vastly larger consumer scale and brand recognition.
• BCG (Boston Consulting Group) - Healthcare & Genetics Practice: Global management consultancy with large healthcare and genomics advisory practices serving Ministries of Health and life sciences companies on precision medicine strategy. Comparable as a competitor for the consultancy side of GENEQ's business but at vastly larger scale and broader scope.

Emerging players

• Nebula Genomics: Direct-to-consumer whole genome and exome sequencing company with privacy-focused positioning. Comparable to GENEQ's DTC exome/genome testing offering in target segment, though operating at consumer scale rather than consultative model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/geneqglobal
• Instagraminstagram.com/geneqglobal
• Facebookfacebook.com/61586351927406

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GENEQ GLOBAL LTD